Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drugs in Development, 2021

November 2021 | 66 pages | ID: B9D8E2A345F5EN
Global Markets Direct

Abstracts

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drugs in Development, 2021

SUMMARY

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Bcl-2-like protein 1 is a protein encoded by the BCL2L1 gene. It belongs to BCL-2 family. It is a potent inhibitor of cell death. It inhibits activation of caspases. It regulates cell death by blocking the voltage-dependent anion channel by binding to it and preventing the release of the caspase activator (CYC1) from the mitochondrial membrane. It acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.

Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 2 respectively. Similarly, the universities portfolio in Phase I and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Musculoskeletal Disorders which include indications Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Myelofibrosis, Polycythemia Vera, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Essential Thrombocythemia, Fibrosis, Gastric Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone-Sensitive Prostate Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lymphoblastic Lymphoma, Lymphoma, Mantle Cell Lymphoma, Metastatic Melanoma, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroendocrine Tumors, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia and Relapsed Multiple Myeloma.

The latest report Bcl 2 Like Protein 1 - Drugs In Development, 2021, outlays comprehensive information on the Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)
• The report reviews Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1)Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Overview
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Companies Involved in Therapeutics Development
AbbVie Inc
Ascenta Therapeutics Inc
Ascentage Pharma Group International
AstraZeneca Plc
Dialectic Therapeutics Inc
Sirnaomics Inc
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Drug Profiles
ABT-737 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-0466 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DT-2216 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
navitoclax dihydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pelcitoclax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology and MRSA Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-369 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Hormone-Sensitive Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Dormant Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Discontinued Products
Bcl 2 Like Protein 1 (Apoptosis Regulator BclX or BCLX or BCL2L1) - Product Development Milestones
Featured News & Press Releases
Nov 04, 2021: Ascentage Pharma to release latest data from pelcitoclax including a Chinese study demonstrating complete response
Sep 13, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor pelcitoclax (APG-1252) combined with osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
Sep 08, 2021: Ascentage Pharma announces latest data of its investigational Bcl-2/Bcl-xL inhibitor Pelcitoclax (APG-1252) combined with Osimertinib in patients with EGFR TKI-resistant non-small cell lung cancer
Aug 20, 2021: Dialectic Therapeutics receives $14.4 million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas
May 19, 2021: Ascentage Pharma announces presentation on pelcitoclax at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 21, 2021: Ascentage Pharma to present data on pelcitoclax (APG-1252) at 2021 ASCO Annual Meeting
Apr 12, 2021: Ascentage Pharma releases preclinical data on Pelcitoclax at AACR Annual Meeting 2021
Mar 03, 2021: Dialectic Therapeutics receives FDA clearance of IND application for lead antiapoptotic protein targeted degradation (APTaD) candidate DT2216
Feb 09, 2021: AZD0466 clinical DEP program global expansion
Oct 08, 2020: Ascentage Pharma's apoptosis-targeting drug candidate granted Orphan Drug Designation by the US FDA
Jul 27, 2020: AZD0466 trial opens MD Anderson Cancer Center as a site
Jun 23, 2020: Starpharma showcased poster presentation on DEP product AZD0466 at AACR 2020
May 31, 2020: Ascentage Pharma presents latest clinical data of APG-1252 drug candidate at the 2020 ASCO
May 15, 2020: Ascentage Pharma to present data on APG-1252 at 2020 AACR Annual Meeting
Feb 26, 2020: Dialectic Therapeutics receives $3 million seed award for product development research from the Cancer Prevention & Research Institute of Texas
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AbbVie Inc, 2021
Pipeline by Ascenta Therapeutics Inc, 2021
Pipeline by Ascentage Pharma Group International, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Dialectic Therapeutics Inc, 2021
Pipeline by Sirnaomics Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021